Repros discontinues highest dose of Proellex in endometriosis trial
This article was originally published in Scrip
Executive Summary
Repros Therapeutics is discontinuing the 50mg dose of its endometriosis candidate, Proellex (CDB-4124), in a Phase II trial, because it lacks therapeutic differentiation from the lower doses of the drug. The 50mg dose was also found to elevate liver enzymes – an indication of toxicity - in a subset of women in the trial who had endometriosis-associated anaemia.